Industry Needs To Be Aware of Serialization Challenges Under DSCSA

US pharmaceutical industry is warned that products “will not flow through the supply chain if the digital data is not right” under DSCSA, says official. Law’s second phase, which takes effect in November, mandates first-ever digital serialization requirements to ward off drug counterfeiting.

The US pharmaceutical industry needs to be well prepared to ensure that all drug packages are correctly serialized beginning Nov. 27 so they are not removed from the supply chain and quarantined, an industry official says. That's when the second phase of the Drug Supply Chain Security Act, or DSCSA, mandates first-ever digital serialization to ward off drug counterfeiting.

Lloyd Mager, global traceability lead for AbbVie Inc., spoke April 24 at the Drug Information Association’s CMC Workshop in...

More from Manufacturing

More from Compliance